<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369846</url>
  </required_header>
  <id_info>
    <org_study_id>XANGMXA20160505</org_study_id>
    <nct_id>NCT04369846</nct_id>
  </id_info>
  <brief_title>A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients</brief_title>
  <official_title>A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate Its Efficacy and Safety Profile in Atopic Dermatitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xantho Biotechnology Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xantho Biotechnology Co., LTD</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in&#xD;
      Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis&#xD;
      Patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase I study is randomized, double-blind, placebo-controlled, dose escalating. There&#xD;
      will be 3 dose cohorts, 4 (up to 8) subjects will be randomized in a 3:1 (GM-XANTHO to&#xD;
      placebo) ratio in each cohort.The total study will take at least 23 days, conducted in&#xD;
      National Taiwan University Hospital with 2-24 healthy subjects being enrolled.The Phase IIa&#xD;
      study is randomized, double-blind, placebo-controlled, parallel. 2:1 ratio for GM-XANTHO to&#xD;
      placebo control. The total study will take at least 43 days, conducted in National Taiwan&#xD;
      University Hospital with 38 Atopic Dermatitis patients being enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment emergent adverse events (TEAEs)</measure>
    <time_frame>7 days for Phase I</time_frame>
    <description>Number of treatment emergent adverse events (TEAEs) occurring during the Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IGA</measure>
    <time_frame>28 days for Phase IIa</time_frame>
    <description>Number of patients achieving IGA of 0 or 1 with a ≥2 point improvement in Phase IIa study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Test drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The arm applies the test drug of GM-XANTHO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The arm applies the placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-XANTHO onitment</intervention_name>
    <description>Onitment application</description>
    <arm_group_label>Test drug group</arm_group_label>
    <other_name>Drawing blood</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo onitment</intervention_name>
    <description>Onitment application</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Drawing blood</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Phase I Number of patients achieving IGA of 0 or 1 with a ≥2 point improvement in Phase IIa&#xD;
        study&#xD;
&#xD;
          -  Female or male, age ≥ 20 years old&#xD;
&#xD;
          -  Subjects whose body mass index (BMI) at screening is within a range of ≥ 18.5 kg/m2&#xD;
             and &lt;30.0 kg/m2.&#xD;
&#xD;
        BMI = Body Weight (kg) / [Height (m) × Height (m)]2&#xD;
&#xD;
          -  Subject's medical history shows no contraindication to the test medications.&#xD;
&#xD;
          -  Subjects judged to be in good health by the investigator based upon the results of&#xD;
             physical examinations (PEs), electrocardiogram (ECG) test, and all items of routine&#xD;
             laboratory tests, including serum biochemistry, hematology and urinalysis, are within&#xD;
             normal range as judged by the site. Assessment items of blood biochemistry include&#xD;
             albumin, total protein, total bilirubin, ALP, SGOT, SGPT, BUN, serum creatinine.&#xD;
             Assessment items of hematology tests include RBC count, WBC with differential counts,&#xD;
             hemoglobin, hematocrit and platelet count. Assessment items of urinalysis include pH,&#xD;
             color, appearance, gravity, erythrocyte, leukocyte, glucose, protein, ketones and&#xD;
             nitrite.&#xD;
&#xD;
          -  Female subjects show negative pregnancy test results and all male and female subjects&#xD;
             with child-bearing potential (between puberty and 2 years after menopause) should use&#xD;
             at least any one of the appropriate contraception methods as shown in inclusion&#xD;
             criteria #12 of phase IIa prior to the first study dose.&#xD;
&#xD;
          -  Subjects did not take any of the following medications in the specified durations:&#xD;
&#xD;
               -  Exposure of test sites to topical medications within 14 days prior to the&#xD;
                  application of IPs&#xD;
&#xD;
               -  Any systemically-absorbed medication (excluding vitamins, food supplements, and&#xD;
                  hormone contraceptives for birth control) within 14 days prior to the first dose&#xD;
                  of the study&#xD;
&#xD;
               -  Any enzyme inducer/inhibitor and/or known hepatic or renal clearance-altering&#xD;
                  agents within 30 days prior to the first dose of the study&#xD;
&#xD;
          -  Subjects are willing to comply with protocol-stated requirements, instructions and&#xD;
             restrictions, followed by understanding and signing the written informed consent form.&#xD;
&#xD;
        Phase IIa&#xD;
&#xD;
          -  Female or male, age ≥ 20 years old&#xD;
&#xD;
          -  Patients who are diagnosed of atopic dermatitis based on the Hanifin and Rajka&#xD;
             Criteria&#xD;
&#xD;
          -  Patients with IGA score between mild (2) to moderate (3) and the Eczema Area and&#xD;
             Severity Indices (EASI) are ≤ 20&#xD;
&#xD;
          -  Patients who have body surface area of atopic dermatitis involvement ≥ 2%, ≤ 20%&#xD;
&#xD;
          -  Patients who agree discontinuation of all treatment modalities, such as topical&#xD;
             antihistamines, topical antimicrobials, topical corticosteroid and light treatments&#xD;
             during the study period for/on the affected site(s) (except the rescue medication&#xD;
             prescribed by the study Investigator(s))&#xD;
&#xD;
          -  Patients who agree discontinuation of systemic corticosteroids, systemic&#xD;
             antihistamines, and systemic immune modulating agents during the study period (except&#xD;
             the standard medication oral antihistamine levocetirizine and rescue medication&#xD;
             prescribed by the study Investigator(s)).&#xD;
&#xD;
          -  Patients are required to stop using treatment drugs listed in criteria #5 for at least&#xD;
             14 days (or longer if the treatment half-life requires so; 7 half-life should have&#xD;
             elapsed) and treatment drugs listed in criteria #6 for 28 days before the first&#xD;
             investigational drug dose administration.&#xD;
&#xD;
          -  Subject is judged to be in general good health (without clinically significant&#xD;
             abnormalities) by the Investigator based on medical history, PEs, ECG, and routine&#xD;
             laboratory tests at screening.&#xD;
&#xD;
          -  Patients who stopped immunosuppressant drugs for at least 28 days prior to the first&#xD;
             dosing&#xD;
&#xD;
          -  Patients who have taken oral antihistamine of levocetirizine 5 mg once daily for at&#xD;
             least 7 days before initiating the study treatment.&#xD;
&#xD;
          -  Patients who are eligible and able to participate in the study and accept to enter the&#xD;
             study by signing written informed consent forms.&#xD;
&#xD;
          -  All male patients and female patients with child-bearing potential (between puberty&#xD;
             and 2 years after menopause) should use at least any one of the appropriate&#xD;
             contraception methods shown below, for during and at least 4 weeks after GM-XANTHO&#xD;
             treatment.&#xD;
&#xD;
               -  Total abstinence [when this is in line with the preferred and usual lifestyle of&#xD;
                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,&#xD;
                  post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
                  contraception].&#xD;
&#xD;
               -  Female sterilization (have had surgical bilateral oophorectomy with or without&#xD;
                  hysterectomy) or tubal ligation at least six weeks before taking study treatment.&#xD;
                  In case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
                  been confirmed by follow up hormone level assessment.&#xD;
&#xD;
               -  Male sterilization. For female subjects on the study, the vasectomized male&#xD;
                  partner should be the sole partner for that subject.&#xD;
&#xD;
               -  Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or&#xD;
                  d.2+d.3):&#xD;
&#xD;
                    -  Use of oral, injected or implanted hormonal methods of contraception or&#xD;
                       other forms of hormonal contraception that have comparable efficacy (failure&#xD;
                       rate &lt;1%), for example hormone vaginal ring or transdermal hormone&#xD;
                       contraception.&#xD;
&#xD;
                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS).&#xD;
&#xD;
                    -  Barrier methods of contraception: Condom or Occlusive cap (diaphragm or&#xD;
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal&#xD;
                       suppository.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Phase I:&#xD;
&#xD;
          -  Subjects with the following conditions at the application site(s) that would interfere&#xD;
             with the IP administration, skin assessment, or reaction to IPs:&#xD;
&#xD;
               -  presence of open sores&#xD;
&#xD;
               -  obvious differences in skin color between applications sites&#xD;
&#xD;
               -  excessive hair&#xD;
&#xD;
               -  scar tissue tattoo&#xD;
&#xD;
               -  coloration&#xD;
&#xD;
          -  Subjects with any properly diagnosed disease within 30 days prior to the first dose of&#xD;
             the study&#xD;
&#xD;
          -  Subjects with any diagnosed dermatological or allergic diseases within 180 days prior&#xD;
             to the first study dose&#xD;
&#xD;
          -  Subjects with any clinically significant hematological, endocrine, cardiovascular,&#xD;
             hepatic, renal, gastrointestinal, and/or pulmonary disorder; subjects with any&#xD;
             predisposing condition that might interfere with the absorption, distribution,&#xD;
             metabolism and excretion of drugs&#xD;
&#xD;
          -  Subjects had participated in investigational drug trials and took any investigational&#xD;
             drug within 60 days prior to the first study dose.&#xD;
&#xD;
          -  Subjects had blood donation for more than 250 mL within 60 days or 500 mL within 90&#xD;
             days prior to the first study dose.&#xD;
&#xD;
          -  Subjects had a history of drug abuse or alcohol abuse according to the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria.&#xD;
&#xD;
          -  Subjects cannot stop smoking and caffeine-intakes for 48 hours prior to the first&#xD;
             study dose and during the entire study period, and 48 hours after the last dose&#xD;
             administration of IPs.&#xD;
&#xD;
          -  Subjects who are inappropriate to participate in this study, as judged by the clinical&#xD;
             Investigator&#xD;
&#xD;
          -  Subjects who have been tested positive for the following tests:&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV)&#xD;
&#xD;
               -  Hepatitis B virus (HBV): HBsAg and anti-HBc&#xD;
&#xD;
               -  Hepatitis C virus (HCV)&#xD;
&#xD;
        Phase IIa:&#xD;
&#xD;
          -  Patients had participated in investigational drug trials and took any investigational&#xD;
             drugs within 30 days or within 5 half-lives of the investigational drugs prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Patients who have any concurrent skin condition that will interfere with assessment of&#xD;
             treatment&#xD;
&#xD;
          -  Patients who have active infection on the atopic dermatitis site(s) at baseline&#xD;
&#xD;
          -  Patients who are inevitable to engage activities involving excessive or prolonged&#xD;
             exposure to sunlight&#xD;
&#xD;
          -  Patients who have known hypersensitivity to the study medication&#xD;
&#xD;
          -  Patients with chronic condition(s) which either is not stable or not well controlled&#xD;
&#xD;
          -  Patients having positive results for HBV, HCV or HIV screens&#xD;
&#xD;
          -  Patients who are pregnant or breast feeding&#xD;
&#xD;
          -  Patients carry history of malignancy of any organ system (other than cervical&#xD;
             carcinoma in situ or localized prostate cancer) within 5 years prior to study entry.&#xD;
&#xD;
          -  Patients who are not suitable to participate in the trial as judged by the&#xD;
             Investigator(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zoe Chen</last_name>
    <phone>+886-2-26557790</phone>
    <email>xanthob@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100225</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guan-Lieng Chen</last_name>
      <phone>+886-2-23560068</phone>
      <phone_ext>813</phone_ext>
      <email>guanlieng.chen@doint.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

